Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | The future of AML treatment? Progress in IDH1/2 inhibitors for AML

The development of IDH inhibitors for acute myeloid leukemia (AML) has been a smoother journey than that for FLT3 inhibitors. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, provides a comprehensive summary of the use of IDH inhibitors for acute myeloid leukemia (AML) treatment. Dr Stone covers the successful trial and subsequent approval of enasidenib for IDH2-mutated advanced AML, as well as the highly anticipated results of a trial investigating ivosidenib monotherapy for IDH1-mutated AML that were presented at the meeting (NCT02074839). Furthermore, he highlights exciting further trials of these drugs in combination regimens that were presented at the meeting (NCT02632708, NCT02677922).